Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Between group comparison of serum concentration of 25(OH)VD3, calcium, phosphorous and hormones and seminal calcium pre and post interventionVariablesTimeVitamin D3(n = 43)Placebo(n = 43)P value (between)25(OH)VD3 (ng/ml)Baseline18.30 ± 6.8719.17 ± 6.420.545a12 weeks32.30 ± 6.3918.93 ± 7.00< 0.001bChange14.00 ± 2.17− 0.23 ± 2.15< 0.001cP value (within)d< 0.0010.482PTH (pg/ml)Baseline32.33 ± 11.1731.34 ± 13.670.714a12 weeks29.96 ± 10.7431.76 ± 13.22< 0.001bChange−2.37 ± 1.360.41 ± 1.54< 0.001cP value (within)d< 0.0010.082OCN (ng/ml)Baseline11.82 ± 4.5212.42 ± 4.160.525a12 weeks11.94 ± 4.6112.35 ± 4.120.663bChange0.11 ± 0.57−0.06 ± 0.450.100cP value (within)d0.1850.334Tt (ng/ml)Baseline3.87 ± 2.083.93 ± 2.040.884a12 weeks3.95 ± 1.753.86 ± 2.010.482bChange0.07 ± 0.64− 0.07 ± 0.360.177cP value (within)d0.4160.199SHBG (nmol/l)Baseline18.80 ± 3.6019.16 ± 4.680.692a12 weeks19.09 ± 3.6918.88 ± 4.710.815bChange0.29 ± 1.22−0.27 ± 1.550.062cP value (within)d0.1250.245E2 (pg/ml)Baseline26.70 ± 12.4625.67 ± 10.870.684a12 weeks26.54 ± 12.5325.61 ± 10.860.095bChange−0.15 ± 0.54−0.05 ± 0.320.311cP value (within)d0.0650.254PRO (mIU/L)Baseline300.13 ± 195.55279.50 ± 158.560.592a12 weeks294.57 ± 188.97280.15 ± 158.140.265bChange−5.56 ± 21.220.64 ± 18.250.149cP value (within)d0.0930.818LH (IU/L)Baseline5.41 ± 4.135.06 ± 2.210.627a12 weeks5.40 ± 4.095.10 ± 2.250.186bChange−0.01 ± 0.260.03 ± 0.180.324cP value (within)d0.6460.292FSH (IU/L)Baseline4.80 ± 4.904.05 ± 3.450.417a12 weeks4.78 ± 4.874.06 ± 4.430.116bChange−0.02 ± 0.150.01 ± 0.110.089cP value (within)d0.0760.123FAI (T/SHBG. 100) (%)Baseline42.54 ± 35.2739.61 ± 23.130.650a12 weeks40.56 ± 22.7139.13 ± 23.720.207bChange−1.97 ± 18.59−0.48 ± 6.140.619cP value (within)d0.4900.608T/LH ratioBaseline1.22 ± 1.480.88 ± 0.530.159a12 weeks1.32 ± 1.580.88 ± 0.560.142bChange0.09 ± 0.29−0.003 ± 0.110.037cP value (within)d0.0320.585T/E2 ratioBaseline0.16 ± 0.100.17 ± 0.080.882a12 weeks0.17 ± 0.080.16 ± 0.070.360bChange0.005 ± 0.03−0.002 ± 0.010.203cP value (within)d0.3160.419Serum Ca (mg/dl)Baseline9.17 ± 0.439.28 ± 0.690.408a12 weeks9.21 ± 0.439.26 ± 0.700. 151bChange0.03 ± 0.08−0.02 ± 0.110.009cP value (within)d0.0080.211Semen Ca (mg/dl)Baseline12.27 ± 3.6412.72 ± 4.140.594a12 weeks12.47 ± 3.6012.57 ± 4.130.218bChange0.15 ± 0.46−0.12 ± 0.720.038cP value (within)d0.0350.270P (mg/dl)Baseline3.52 ± 0.723.73 ± 0.790.219a12 weeks3.62 ± 0.713.65 ± 0.80.470bChange0.04 ± 0.11−0.08 ± 0.410.049cP value (within)d0.0090.19025(OH)VD3, 25-hydroxy vitamin D3; PTH, parathyroid hormone; OCN, osteocalcin; T, testosterone; SHBG, sex hormone-binding globulin; E2, estradiol; FAI, free androgen index; PRO, prolactin; LH, luteinizing hormone; FSH, follicle-stimulating hormone; Ca, calcium and P, phosphorus: Values are reported as mean ± standard deviation or Frequency and percent: Between groups differences pre intervention, the p value are reported using the independent sample t test (a): Between groups differences post intervention; the p value is reported using the analysis of covariance (ANCOVA) (b): Between groups comparing the changes of variables, the p value is reported using the independent sample t test (c): Within group difference, the p value is reported using the paired t test (d)-P < 0.05 was considered significant

Source: Serum 25(OH)VD3, PTH and OCN concentration. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Triple-blind reported · Human research reported

Reported blinded roles: patients.

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

The effects of Vitamin D3 supplementation on Spermatogram and endocrine factors in asthenozoospermia infertile men: a randomized, triple blind, placebo-controlled clinical trial

Source: Article title.

Patients were randomly allocated to groups A and B, who received daily 4000 IU VD3 and matching placebo respectively for 3 months.

Source: Abstract.

To decrease the probability of bias, the investigator, statistical analyzer, and patients were masked to the treatment situation.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

The effects of Vitamin D3 supplementation on Spermatogram and endocrine factors in asthenozoospermia infertile men: a randomized, triple blind, placebo-controlled clinical trial

Study design awaiting verification · Reproductive Biology and Endocrinology : RB&E · 2021

Original publication title

The effects of Vitamin D3 supplementation on Spermatogram and endocrine factors in asthenozoospermia infertile men: a randomized, triple blind, placebo-controlled clinical trial

Leila Maghsoumi-Norouzabad; Ahmad Zare Javid; Anahita Mansoori; Mohammadreza Dadfar; Amirarsalan Serajian

© The Author(s) 2021

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

VD3 supplementation may affect sperm motility in men with asthenozoospermia and serum 25(OH)VD3 < 30 ng/ml.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

Evaluate the effects of vitamin D3 (VD3) on sperm parameters and endocrine markers in infertile men with asthenozoospermia.

Source: Objective

Abstract: What methods does the paper describe?

This randomized, triple-masking, placebo-controlled clinical trial conducted on 86 asthenozoospermia infertile men with serum 25 hydroxy vitamin D3 (25(OH)VD3) < 30 ng/ml in the infertility clinic of Ahvaz Jahad daneshgahi, Iran. Patients were randomly allocated to groups A and B, who received daily 4000 IU VD3 and matching placebo respectively for 3 months. Demographic data, dietary intake, physical activity, sun exposure, anthropometric indices, serum 25(OH)VD3, luteinizing hormone (LH), follicle-stimulating hormone (FSH), total testosterone (T), estradiol (E2),, sex hormone-binding globulin (SHBG), free androgen index (FAI = T/SHBG. 100), T/LH and T/E2 ratios, prolactin (PRO), parathyroid hormone (PTH), osteocalcin (OCN), phosphorus and sperm parameters were assessed.

Source: Materials and methods

Abstract: Results

Three months VD3 supplementation with 4000 IU/day had no significant effects body weight, body mass index (BMI), waist circumference (WC), body fat (BF), serum, OCN, LH, FSH, T, E2, SHBG, PRO, T/E2 ratio, FAI, semen volume, sperm count and normal sperm morphology. It increases serum 25(OH)VD3, PTH and phosphorus and seminal and serum calcium, T/LH ratio and total and progressive sperm motility and decreased significantly compared to the baseline and placebo group.

Source: Results

Abstract: Conclusion

VD3 supplementation may affect sperm motility in men with asthenozoospermia and serum 25(OH)VD3 < 30 ng/ml.

Source: Conclusion
Authors’ abstract

Objective

Evaluate the effects of vitamin D3 (VD3) on sperm parameters and endocrine markers in infertile men with asthenozoospermia.

Materials and methods

This randomized, triple-masking, placebo-controlled clinical trial conducted on 86 asthenozoospermia infertile men with serum 25 hydroxy vitamin D3 (25(OH)VD3) < 30 ng/ml in the infertility clinic of Ahvaz Jahad daneshgahi, Iran. Patients were randomly allocated to groups A and B, who received daily 4000 IU VD3 and matching placebo respectively for 3 months. Demographic data, dietary intake, physical activity, sun exposure, anthropometric indices, serum 25(OH)VD3, luteinizing hormone (LH), follicle-stimulating hormone (FSH), total testosterone (T), estradiol (E2),, sex hormone-binding globulin (SHBG), free androgen index (FAI = T/SHBG. 100), T/LH and T/E2 ratios, prolactin (PRO), parathyroid hormone (PTH), osteocalcin (OCN), phosphorus and sperm parameters were assessed.

Results

Three months VD3 supplementation with 4000 IU/day had no significant effects body weight, body mass index (BMI), waist circumference (WC), body fat (BF), serum, OCN, LH, FSH, T, E2, SHBG, PRO, T/E2 ratio, FAI, semen volume, sperm count and normal sperm morphology. It increases serum 25(OH)VD3, PTH and phosphorus and seminal and serum calcium, T/LH ratio and total and progressive sperm motility and decreased significantly compared to the baseline and placebo group.

Conclusion

VD3 supplementation may affect sperm motility in men with asthenozoospermia and serum 25(OH)VD3 < 30 ng/ml.

Trial registration

Iran Clinical Trials Registry, ID: IRCT20151128025274N4, registered on 28 March 2018, URL of trial registry record: https://www.irct.ir/trial/29983

Publication and source details

Original title: The effects of Vitamin D3 supplementation on Spermatogram and endocrine factors in asthenozoospermia infertile men: a randomized, triple blind, placebo-controlled clinical trial

Leila Maghsoumi-Norouzabad; Ahmad Zare Javid; Anahita Mansoori; Mohammadreza Dadfar; Amirarsalan Serajian

Reproductive Biology and Endocrinology : RB&E · 2021

© The Author(s) 2021https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T01:47:12.188025+00:00

DOI: 10.1186/s12958-021-00789-y · PMC8256550